Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases

Background: To analyze the outcomes of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (SRT) and to study the impact of the sequence between the two modalities. Methods: The authors reviewed the records of 51 p...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2022-09, Vol.10 (9), p.2249
Main Authors: Porte, Judith, Saint-Martin, Caroline, Frederic-Moreau, Thomas, Massiani, Marie-Ange, Bozec, Laurence, Cao, Kim, Verrelle, Pierre, Otz, Joelle, Jadaud, Eric, Minsat, Mathieu, Langer, Adriana, Girard, Nicolas, Créhange, Gilles, Beddok, Arnaud
Format: Article
Language:English
Subjects:
brain metastases
Cancer therapies
Chemotherapy
Drug therapy
Edema
Immune checkpoint
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Metastases
Metastasis
non-small cell lung cancer
Non-small cell lung carcinoma
Patient outcomes
Patients
Radiation therapy
Radiosurgery
Radiotherapy
Small cell lung carcinoma
stereotactic radiotherapy
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: To analyze the outcomes of patients with brain metastases (BM) from non-small cell lung cancer (NSCLC) treated with immunotherapy (IT) and stereotactic radiotherapy (SRT) and to study the impact of the sequence between the two modalities. Methods: The authors reviewed the records of 51 patients with 84 BM from NSCLC treated at Institut Curie with IT and SRT. BM were categorized into three groups: ‘SRT before IT’, ‘concurrent SRT and IT’, and ‘SRT after IT.’ Regional progression-free interval (R-PFI) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: After a median follow-up from SRT of 22.5 months (2.7–47.3), the 1-year and 2-year OS were 69.7% (95%CI [58.0–83.8]) and 44.0% [30.6–63.2], respectively. Concerning distant intracranial control, the 1-year and 2-year R-PFI were 40.1% [30.1–53.3] and 35.2% [25.1–49.4], respectively. Moreover, one-year R-PFI in ‘SRT before IT’, ‘concurrent SRT and IT’, and ‘SRT after IT’ groups were 24.1%, 49.6%, and 34.2%, respectively (p = 0.094). The type of therapeutic sequence did not appear to impact the risk of brain necrosis. Conclusions: The concurrent administration of SRT and IT appeared to offer the best locoregional control, without increasing the risk of toxicity, compared to patients treated with SRT before or after IT.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10092249